Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) Rises By 79.8%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) was the recipient of a significant growth in short interest in June. As of June 15th, there was short interest totaling 1,130,432 shares, a growth of 79.8% from the May 31st total of 628,655 shares. Based on an average daily volume of 279,068 shares, the short-interest ratio is currently 4.1 days. Approximately 2.9% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded shares of Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Coeptis Therapeutics Stock Down 8.6%

ZSQR opened at $10.99 on Friday. The firm has a market cap of $565.22 million, a P/E ratio of -4.36 and a beta of -0.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.25. The business has a 50 day moving average price of $12.09 and a 200 day moving average price of $12.62. Coeptis Therapeutics has a twelve month low of $7.41 and a twelve month high of $21.41.

Coeptis Therapeutics (NASDAQ:ZSQR) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%. The company had revenue of $0.11 million for the quarter.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC lifted its position in Coeptis Therapeutics by 100.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after acquiring an additional 2,500 shares during the last quarter. Yorkville Advisors Global LP acquired a new stake in shares of Coeptis Therapeutics in the third quarter valued at about $140,000. Marshall Wace LLP bought a new position in shares of Coeptis Therapeutics in the fourth quarter worth about $259,000. State Street Corp increased its stake in shares of Coeptis Therapeutics by 35.0% in the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after purchasing an additional 6,962 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after purchasing an additional 4,721 shares during the last quarter. Institutional investors own 13.88% of the company’s stock.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.